The world is in the midst of a huge fundamental shift in fibre supply, demand balances, and policy changes. Governments around the world are introducing policy changes which influence the supply demand balance as the politicians' thoughts are uttered. Government agencies and their bureaucrats are imposing changes on industry even before the legislation is passed by the government in question.
This ad hoc change process will continue for a time to come until the countries in question show a tough-mindedness with regard to their land use policies. Policies affecting forest areas such as protection areas, Native land claims, the protection of biodiversity and a true goal of sustainable development ; which addresses the combined issues of cultural, environmental, social and economic matters.
Eventually all of these difficult issues will reach essential closure. Then there will be great new opportunities for investment to meet the growing demand for forest products ; leading to a strengthening competitive position in the more traditional producing areas such as Canada.

抄録全体を表示

Seven hundred fifty mg of cholesterol were fed daily to 32 patients of the ischemic heart disease (IHD) for 2 weeks. Cholesterol amounts in VLDL, LDL, HDL, HDL₂ and were estimated on the th, th and 14th days of cholesterol load. Plasma apoprotein A-I, A-II, , -II, levels were also measured in 16 from 32 IHD subjects. Apoprotein levels were estimated by a method of single radial immunodiffusion (SRID). Before cholesterol administration, cholesterol amounts in VLDL, LDL, HDL, HDL₂ and were 15.±.5mg/dl (mean±SD), 150.±58.mg/dl 43.±.mg/dl, 16.±5.mg/dl and 24.±.mg/dl respectively. Plasma apoprotein A-I, A-II, , -II and levels were 81.±. mg/dl, 15.±5.mg/dl, 93.±36.mg/dl, .±.00mg/dl and .29±.36mg/dl respectively. After 2 weeks' cholesterol feeding, all plasma lipoprotein cholesterol and apoprotein levels did not change significantly. Correlation coefficients between plasma apoprotein and lipoprotein cholesterol levels were calculated. Apoprotein A-I and A-II correlated with HDL- (r=.348), HDL₂- (r=.612) and (r=.569). Apoprotein correlated with total cholesterol (TC) (r=.610), VLDL- (r=.341), LDL- (r=.726), HDL- (r=.432) and HDL₂- (r=.465). Apoprotein -II correlated with TC (r=.765), TG (r=.679), VLDL- (r=.651), LDL- (r=.461) and HDL₂- (r=.326). Apoprotein correlated with TC (r=.580), TG (r=.575) and VLDL- (r=.666). Interapoprotein's correlations were also calculated. Apoprotein A-I correlated with apoprotein A-II (r=.468). Apoprotein correlated with apoprotein -II (r=.393). Apoprotein -II correlated with apoprotein (r=.393) and (r=.549). Apoprotein only correlated with apoprotein -II (r=.549).

抄録全体を表示